JP2020531543A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531543A5
JP2020531543A5 JP2020511528A JP2020511528A JP2020531543A5 JP 2020531543 A5 JP2020531543 A5 JP 2020531543A5 JP 2020511528 A JP2020511528 A JP 2020511528A JP 2020511528 A JP2020511528 A JP 2020511528A JP 2020531543 A5 JP2020531543 A5 JP 2020531543A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
hours
subject
amantadine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047754 external-priority patent/WO2019040748A1/en
Publication of JP2020531543A publication Critical patent/JP2020531543A/ja
Publication of JP2020531543A5 publication Critical patent/JP2020531543A5/ja
Priority to JP2022183927A priority Critical patent/JP2023009251A/ja
Priority to JP2024139596A priority patent/JP2024159885A/ja
Pending legal-status Critical Current

Links

JP2020511528A 2017-08-24 2018-08-23 アマンタジン組成物、その調製、および使用方法 Pending JP2020531543A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022183927A JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549921P 2017-08-24 2017-08-24
US62/549,921 2017-08-24
PCT/US2018/047754 WO2019040748A1 (en) 2017-08-24 2018-08-23 AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183927A Division JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法

Publications (2)

Publication Number Publication Date
JP2020531543A JP2020531543A (ja) 2020-11-05
JP2020531543A5 true JP2020531543A5 (enExample) 2021-09-24

Family

ID=65439620

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511528A Pending JP2020531543A (ja) 2017-08-24 2018-08-23 アマンタジン組成物、その調製、および使用方法
JP2022183927A Pending JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A Pending JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022183927A Pending JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A Pending JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Country Status (10)

Country Link
US (3) US11077073B2 (enExample)
EP (1) EP3672581A4 (enExample)
JP (3) JP2020531543A (enExample)
CN (2) CN117860718A (enExample)
AU (2) AU2018320946B2 (enExample)
BR (1) BR112020003375A2 (enExample)
CA (1) CA3072764A1 (enExample)
IL (1) IL272834B2 (enExample)
MX (2) MX2020002078A (enExample)
WO (1) WO2019040748A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use
US11441653B1 (en) 2021-05-20 2022-09-13 Dana Automotive Systems Group, Llc Integrated gearbox in electric motor systems

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JP2623099B2 (ja) 1987-11-06 1997-06-25 株式会社ニフコ スライダの引込み装置
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2003516345A (ja) 1999-12-09 2003-05-13 アルザ・コーポレーション 抗ウイルス剤
US20030190360A1 (en) 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
US20060198815A1 (en) 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
CA2454200A1 (en) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20030045577A1 (en) 2001-08-15 2003-03-06 Madhat Maher N. Method for preventing infectious respiratory diseases
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
WO2003101458A1 (en) 2002-05-31 2003-12-11 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
ES2323268T3 (es) 2002-07-29 2009-07-10 Glaxo Group Ltd Formulaciones de liberacion prolongada que contienen lamotrigina.
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060024366A1 (en) 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
MXPA06003101A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
EP1670442A4 (en) 2003-09-19 2011-09-14 Penwest Pharmaceuticals Co DOSAGE FORMS WITH DELAYED RELEASE
WO2005079779A1 (en) 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7211275B2 (en) 2004-01-16 2007-05-01 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
AU2005209310B2 (en) 2004-01-29 2011-01-06 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions
US20050245460A1 (en) 2004-02-13 2005-11-03 Meyerson Laurence R Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
EP1742624B1 (en) 2004-02-18 2010-01-06 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CN1968684A (zh) 2004-06-17 2007-05-23 森林实验室公司 美金刚的调释制剂
JP2006079138A (ja) 2004-09-07 2006-03-23 Ricoh Co Ltd ステータス取得方法、プリンタドライバ及び情報処理装置
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20190008799A1 (en) 2004-11-23 2019-01-10 Adamas Pharma, Llc Composition for administering an nmda receptor antagonist to a subject
MX2007006120A (es) 2004-11-23 2007-12-07 Adamas Pharmaceuticals Inc Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US20190328684A1 (en) 2004-11-24 2019-10-31 Adamas Pharma, Llc Composition and method for treating neurological disease
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) * 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8252331B2 (en) 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US20080279819A1 (en) 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
US20080248107A1 (en) 2005-08-24 2008-10-09 Rubicon Research Pvt. Ltd. Controlled Release Formulation
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
EP2063871A1 (en) 2006-08-30 2009-06-03 Jagotec AG Controlled release solid oral dosage formulations comprising nisoldipine
EP1961414A1 (en) 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition comprising a recombinant gelatin
US8779090B2 (en) * 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US8313770B2 (en) 2007-05-30 2012-11-20 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US8247438B2 (en) * 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
WO2010017821A1 (en) 2008-08-14 2010-02-18 Daniel Bar-Shalom Coated tablets with a remaining degradation surface over the time8
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
CA2755808C (en) 2009-03-18 2016-01-19 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
WO2010111232A2 (en) 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
CA2757337A1 (en) 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US8895662B2 (en) 2010-12-31 2014-11-25 Eternal Chemical Co., Ltd. Curable composition and method for manufacturing the same
US20130236544A1 (en) * 2012-03-08 2013-09-12 Dr. Reddy's Laboratories Ltd. Stable pharmaceutical compositions of fesoterodine
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
AU2015343199B2 (en) 2014-11-04 2021-04-08 Adamas Pharma, Llc Methods of administering amantadine compositions
GB201516037D0 (en) 2015-09-10 2015-10-28 Agco Int Gmbh Vehicle axel assembly
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use

Similar Documents

Publication Publication Date Title
TW389696B (en) Accelerated release composition containing bromocriptine
JP2020531543A5 (enExample)
CA3105341C (en) Methods of normalizing amino acid metabolism
JP2008520736A5 (enExample)
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP2005528430A5 (enExample)
CZ20024110A3 (cs) Léčivo pro léčení poruch spánku
AU2001264736A1 (en) Gabapentin analogues for sleep disorders
JP2018507243A5 (enExample)
JP2016504384A5 (enExample)
JP2013512919A5 (enExample)
JP2002520277A (ja) 不眠症を治療する方法
JP2017533211A5 (enExample)
JP2010065060A (ja) 心不全処置のための複合治療
JP2017528521A5 (enExample)
JP2019218379A5 (enExample)
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JP2016505050A5 (enExample)
JPH10505087A (ja) 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
JP2019507786A5 (enExample)
JP2019531286A5 (enExample)
JPS61286326A (ja) パ−キンソン病治療薬
US20110117070A1 (en) Compositions and methods for treating headache
JP2006528949A5 (enExample)
JP2019535830A5 (enExample)